Valerio Therapeutics Société anonyme (ALVIO.PA)
EUR 0.08
(3.31%)
EUR 0.08
(3.31%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 8.99 Million EUR | -10.8% |
| 2022 | 10.08 Million EUR | -31.67% |
| 2021 | 14.76 Million EUR | 135.96% |
| 2020 | 6.25 Million EUR | -24.44% |
| 2019 | 8.28 Million EUR | 17.58% |
| 2018 | 7.04 Million EUR | 5317.69% |
| 2017 | 130 Thousand EUR | 22.64% |
| 2016 | 106 Thousand EUR | 53.62% |
| 2015 | 69 Thousand EUR | -95.77% |
| 2014 | 1.62 Million EUR | 1687.26% |
| 2013 | 91.18 Thousand EUR | 60.16% |
| 2012 | 56.93 Thousand EUR | -66.51% |
| 2011 | 170.01 Thousand EUR | 197.95% |
| 2010 | 57.06 Thousand EUR | -23.43% |
| 2009 | 74.52 Thousand EUR | 537.52% |
| 2008 | 11.68 Thousand EUR | -45.62% |
| 2007 | 21.49 Thousand EUR | -61.63% |
| 2006 | 56.02 Thousand EUR | -92.07% |
| 2005 | 706.41 Thousand EUR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 12.74 Million EUR | 41.69% |
| 2024 Q2 | 12.74 Million EUR | 3.71% |
| 2023 Q4 | 8.99 Million EUR | -15.67% |
| 2023 Q3 | 10.66 Million EUR | 11.88% |
| 2023 FY | 8.99 Million EUR | -10.8% |
| 2023 Q2 | 9.53 Million EUR | -28.09% |
| 2023 Q1 | 13.26 Million EUR | 31.47% |
| 2022 Q1 | 14.35 Million EUR | -2.76% |
| 2022 FY | 10.08 Million EUR | -31.67% |
| 2022 Q4 | 10.08 Million EUR | 2.95% |
| 2022 Q3 | 9.79 Million EUR | -42.74% |
| 2022 Q2 | 17.11 Million EUR | 19.2% |
| 2021 FY | 14.76 Million EUR | 135.96% |
| 2021 Q1 | 10.05 Million EUR | 60.76% |
| 2021 Q3 | 9.46 Million EUR | -10.21% |
| 2021 Q4 | 14.76 Million EUR | 56.02% |
| 2021 Q2 | 10.53 Million EUR | 4.77% |
| 2020 Q3 | 5.78 Million EUR | -21.73% |
| 2020 Q2 | 7.38 Million EUR | 6.27% |
| 2020 Q4 | 6.25 Million EUR | 8.25% |
| 2020 FY | 6.25 Million EUR | -24.44% |
| 2020 Q1 | 6.94 Million EUR | -16.09% |
| 2019 Q1 | 9.78 Million EUR | 39.0% |
| 2019 FY | 8.28 Million EUR | 17.58% |
| 2019 Q4 | 8.28 Million EUR | 1.66% |
| 2019 Q3 | 8.14 Million EUR | -20.44% |
| 2019 Q2 | 10.23 Million EUR | 4.59% |
| 2018 Q1 | 101 Thousand EUR | -22.31% |
| 2018 Q2 | 7.16 Million EUR | 6997.03% |
| 2018 Q3 | 6.91 Million EUR | -3.6% |
| 2018 Q4 | 7.04 Million EUR | 1.92% |
| 2018 FY | 7.04 Million EUR | 5317.69% |
| 2017 Q1 | 155 Thousand EUR | 46.23% |
| 2017 FY | 130 Thousand EUR | 22.64% |
| 2017 Q4 | 130 Thousand EUR | 0.0% |
| 2017 Q3 | 130 Thousand EUR | -97.33% |
| 2017 Q2 | 4.87 Million EUR | 3041.94% |
| 2016 FY | 106 Thousand EUR | 53.62% |
| 2016 Q3 | 106 Thousand EUR | 49.3% |
| 2016 Q2 | 71 Thousand EUR | 0.0% |
| 2016 Q1 | 71 Thousand EUR | 2.9% |
| 2016 Q4 | 106 Thousand EUR | 0.0% |
| 2015 Q2 | 1.77 Million EUR | 0.0% |
| 2015 Q4 | 69 Thousand EUR | 0.0% |
| 2015 FY | 69 Thousand EUR | -95.77% |
| 2015 Q1 | 1.77 Million EUR | 9.05% |
| 2015 Q3 | 69 Thousand EUR | -96.12% |
| 2014 Q3 | 1.63 Million EUR | 1391.42% |
| 2014 Q4 | 1.62 Million EUR | -0.02% |
| 2014 Q2 | 109.29 Thousand EUR | 0.0% |
| 2014 FY | 1.62 Million EUR | 1687.26% |
| 2014 Q1 | 109.29 Thousand EUR | 19.86% |
| 2013 Q4 | 91.18 Thousand EUR | 0.0% |
| 2013 FY | 91.18 Thousand EUR | 60.16% |
| 2013 Q3 | 91.18 Thousand EUR | -18.96% |
| 2013 Q2 | 112.51 Thousand EUR | 0.0% |
| 2013 Q1 | 112.51 Thousand EUR | 97.63% |
| 2012 FY | 56.93 Thousand EUR | -66.51% |
| 2012 Q2 | 69.93 Thousand EUR | 0.0% |
| 2012 Q4 | 56.93 Thousand EUR | 0.0% |
| 2011 Q4 | 170.01 Thousand EUR | 0.0% |
| 2011 FY | 170.01 Thousand EUR | 197.95% |
| 2011 Q2 | 2.23 Million EUR | 0.0% |
| 2010 FY | 57.06 Thousand EUR | -23.43% |
| 2010 Q4 | 57.06 Thousand EUR | 0.0% |
| 2010 Q2 | 1.41 Million EUR | 0.0% |
| 2009 Q4 | 74.52 Thousand EUR | 0.0% |
| 2009 FY | 74.52 Thousand EUR | 537.52% |
| 2008 FY | 11.68 Thousand EUR | -45.62% |
| 2007 FY | 21.49 Thousand EUR | -61.63% |
| 2006 FY | 56.02 Thousand EUR | -92.07% |
| 2005 FY | 706.41 Thousand EUR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | 3.39 Million EUR | -165.428% |
| ABIVAX Société Anonyme | 55.46 Million EUR | 83.777% |
| Adocia SA | 13.08 Million EUR | 31.25% |
| Aelis Farma SA | 4.03 Million EUR | -122.833% |
| Biophytis S.A. | 8.27 Million EUR | -8.803% |
| Advicenne S.A. | 17.42 Million EUR | 48.362% |
| genOway Société anonyme | 7.23 Million EUR | -24.395% |
| IntegraGen SA | 1.12 Million EUR | -700.011% |
| Medesis Pharma S.A. | 1.2 Million EUR | -649.833% |
| Neovacs S.A. | 650 Thousand EUR | -1284.308% |
| NFL Biosciences SA | 62.17 Thousand EUR | -14372.287% |
| Plant Advanced Technologies SA | 4.35 Million EUR | -106.542% |
| Quantum Genomics Société Anonyme | 2.71 Million EUR | -231.194% |
| Sensorion SA | 2.86 Million EUR | -213.652% |
| Theranexus Société Anonyme | 3.64 Million EUR | -146.993% |
| TME Pharma N.V. | 1.16 Million EUR | -671.698% |
| Valbiotis SA | 6.87 Million EUR | -30.823% |
| TheraVet SA | 1.15 Million EUR | -675.779% |
| argenx SE | 18.1 Million EUR | 50.302% |
| BioSenic S.A. | 28.16 Million EUR | 68.048% |
| Celyad Oncology SA | 902 Thousand EUR | -897.561% |
| DBV Technologies S.A. | 13.01 Million USD | 30.884% |
| Galapagos NV | 9.59 Million EUR | 6.232% |
| Genfit S.A. | 70.17 Million EUR | 87.178% |
| GeNeuro SA | 7.73 Million EUR | -16.286% |
| Hyloris Pharmaceuticals SA | 5.29 Million EUR | -69.966% |
| Innate Pharma S.A. | 39.89 Million EUR | 77.445% |
| Inventiva S.A. | 37.4 Million EUR | 75.946% |
| MaaT Pharma SA | 14.07 Million EUR | 36.071% |
| MedinCell S.A. | 58.96 Million EUR | 84.739% |
| Nanobiotix S.A. | 50.56 Million EUR | 82.205% |
| Onward Medical N.V. | 16.87 Million EUR | 46.675% |
| Oryzon Genomics S.A. | 13.68 Million EUR | 34.26% |
| OSE Immunotherapeutics SA | 45.8 Million EUR | 80.354% |
| Oxurion NV | 12.33 Million EUR | 27.047% |
| Pharming Group N.V. | 155.29 Million EUR | 94.206% |
| Poxel S.A. | 46.9 Million EUR | 80.814% |
| GenSight Biologics S.A. | 18.42 Million EUR | 51.172% |
| Transgene SA | 1.25 Million EUR | -615.831% |
| Financière de Tubize SA | 79.2 Million EUR | 88.639% |
| UCB SA | 3.03 Billion EUR | 99.704% |
| Valneva SE | 208.81 Million EUR | 95.691% |
| Vivoryon Therapeutics N.V. | 38 Thousand EUR | -23578.947% |